Core Insights - Several companies have experienced significant stock price increases, attracting investor attention and market analysis [1] Company Summaries - **Xenetic Biosciences, Inc.**: Achieved a 142.31% increase in stock price, closing at $10.39, with a trading volume of 45,373,947. The company focuses on immuno-oncology technologies and has expanded its partnership with The Scripps Research Institute to advance CAR T-cell therapies [2] - **bioAffinity Technologies, Inc.**: Stock price rose by 108.60% to $0.48, with a volume of 29,850. The company specializes in non-invasive cancer diagnosis and treatment, showcasing the clinical value of its CyPath® Lung in detecting early-stage lung cancer [3] - **GigCapital7 Corp.**: Recorded an 89.43% increase in stock price, ending at $1.58. This SPAC is gaining interest due to its business combination with BigBear.ai, which has a pro forma enterprise value of $1.378 billion and aims to capitalize on AI/ML market opportunities [4] - **AlphaTON Capital Corp.**: Experienced an 85.48% rise in stock price to $10.35. The company is transitioning to a digital asset treasury model focused on Toncoin (TON) and is exploring the tokenization of single-indication economics for mesothelioma [5] - **Acurx Pharmaceuticals, Inc.**: Stock price increased by 74.36% to $7.48. The company is developing antibiotics for bacterial infections and received a positive opinion from the European Medicines Agency for its Pediatric Investigation Plan, positioning it for international Phase 3 clinical trials [6] Market Dynamics - The performances of these companies illustrate the dynamic nature of the stock market and the potential for significant returns, prompting investors and analysts to monitor future developments closely [7][8]

New to The Street, one of America's longest-running business television brands, announces tonight's nationwide broadcast on Fox Business at 10:30 PM PST. The episode features exclusive interviews with NeOnc Technologies (NASDAQ:NTHI), FLOKI, XION, Sharps Technology (NASDAQ:STSS), and Aeries Technology (NASDAQ:AERT), each highlighting their innovation, growth, and leadership in their respective sectors.The segment continues New to The Street's mission to spotlight cutting-edge companies and emerging leaders ...

Accessibility StatementSkip Navigation STATEN ISLAND, N.Y., Sept. 30, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company") is a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections announced receipt of a favorable opinion from the PDCO of the EMA on Acurx's Pediatric Investigation Plan (PIP) for ibezapolstat use in children with C. difficile infection (CDI). * Adapted from: Shirley DA, Torn ...

Financial Data and Key Metrics Changes - The company ended Q2 2025 with cash totaling $6.1 million, an increase from $3.7 million as of December 31, 2024 [14] - The net loss for Q2 2025 was $2.2 million or $1.89 per diluted share, compared to a net loss of $4.1 million or $5.21 per diluted share for Q2 2024 [17] - For the first half of 2025, the net loss was $4.4 million or $4.01 per diluted share, down from $8.5 million or $10.84 per diluted share in the same period of 2024 [17] Business Line Data and Key Metrics Changes - Research and development expenses for Q2 2025 were $500,000, a decrease from $1.8 million in Q2 2024, primarily due to reduced manufacturing and consulting costs [14] - General and administrative expenses for Q2 2025 were $1.7 million, down from $2.3 million in Q2 2024, mainly due to a decrease in share-based compensation [15] Market Data and Key Metrics Changes - The company announced a new patent granted by the Indian Patent Office for its DNA polymerase 3C inhibitors, expiring in December 2039, which supports its antibiotic development program [6] - The publication of Phase 2 clinical trial data for ibezaprolstat in treating C. difficile infection was highlighted, showcasing its potential as a novel antibiotic treatment [8][10] Company Strategy and Development Direction - The company is pursuing a multi-step approach to raise capital through customary financings, warrant inducements, and public-private partnerships [7] - A reverse stock split was implemented to comply with NASDAQ listing requirements, indicating a focus on maintaining compliance and financial stability [12] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ongoing development of ibezaprolstat and its potential to address urgent medical needs, particularly in the context of rising antimicrobial resistance [12] - The company anticipates continued cash preservation and a reduction in operating expenses, with a cash burn rate expected to remain around $400,000 per month [25] Other Important Information - The company is considering alternative financial pathways to support its Phase 3 clinical trial program for ibezapolumab [12] - The FDA has granted QIDP and fast track designations for Edezapolstat, emphasizing its importance in the treatment landscape for C. difficile infections [12] Q&A Session Summary Question: Will the trend of reduced operating expenses continue into 2025 and 2026? - Management confirmed that the trend of cash preservation and reduced operating expenses is expected to continue through the second half of 2025 and into 2026 [20][24] Question: When can partnerships be anticipated? - Management indicated that partnerships could be announced in the second half of 2025, but the timeline may extend into 2026 due to external factors [21][22] Question: Any feedback from the physician community regarding the recent publication? - Management noted that the only rate-limiting step ahead of the Phase III studies is related to the fill-finish process of ibezaprolstat supply, which is not expected to cause significant delays [30][31]

Core Viewpoint - Acurx Pharmaceuticals reported its financial and operational results for Q2 2025, highlighting a significant reduction in losses and an increase in cash reserves, while continuing to advance its antibiotic development programs. Financial Highlights - The company raised approximately $2.7 million from warrant exercises, resulting in net proceeds of $2.5 million after fees [1] - Cash position improved to $6.1 million as of June 30, 2025, up from $3.7 million at the end of 2024 [2] - Total gross proceeds raised in Q2 2025 amounted to approximately $3.4 million through an equity line of credit and warrant inducement [2] Research and Development Expenses - R&D expenses for Q2 2025 were $0.5 million, a decrease of $1.3 million from $1.8 million in Q2 2024, primarily due to lower manufacturing and consulting costs [3] - For the first half of 2025, R&D expenses totaled $1.1 million, down from $3.4 million in the same period of 2024, reflecting a reduction in both manufacturing and consulting costs [3] General and Administrative Expenses - G&A expenses for Q2 2025 were $1.7 million, down from $2.3 million in Q2 2024, mainly due to a decrease in share-based compensation and professional fees [4][5] - For the first half of 2025, G&A expenses were $3.3 million compared to $5.1 million in the same period of 2024, indicating a significant reduction [5] Net Income/Loss - The company reported a net loss of $2.2 million or $1.89 per diluted share for Q2 2025, an improvement from a net loss of $4.1 million or $5.21 per diluted share in Q2 2024 [6] - For the first half of 2025, the net loss was $4.4 million or $4.01 per diluted share, compared to a net loss of $8.5 million or $10.84 per diluted share in the same period of 2024 [6] Operational Developments - Acurx received a new patent for its DNA polymerase IIIC inhibitors, expiring in December 2039, which supports its antibiotic development program targeting infections caused by MRSA, VRE, DRSP, and Anthrax [4] - The company closed an equity line of credit with Lincoln Park Capital for up to $12 million in May 2025 [4] - Acurx announced the publication of Phase 2b clinical trial data for ibezapolstat in a leading microbiology journal in June 2025 [4] - The company is preparing for international Phase 3 clinical trials for ibezapolstat, which has received positive regulatory guidance from the EMA [10] Share Structure - As of June 30, 2025, the company had 1,470,352 shares outstanding following a 1 for 20 reverse stock split [7]

FORM 10-Q (Mark one) ☒ Quarterly Report Under Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Quarterly Period Ended June 30, 2025 Or ☐ Transition Report Under Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number 001-40536 Acurx Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) | Delaware | 82-3733567 | | --- | --- | | State or other jurisdiction of | (I.R.S. Employer | | incorporation or organization | Identification No.) | | 259 Li ...

Core Viewpoint - Acurx Pharmaceuticals has announced a 1-for-20 reverse stock split to increase its stock price and regain compliance with Nasdaq's minimum bid price requirement, effective August 4, 2025 [1][3]. Group 1: Reverse Stock Split Details - The reverse stock split will convert every twenty shares of common stock into one share, with no fractional shares issued; stockholders will receive cash for any fractional shares [2]. - The number of outstanding shares will decrease from approximately 30,764,540 to about 1,538,227, while the total authorized shares will remain unchanged [3]. - Stockholders holding shares electronically will not need to take action, while those with physical certificates will receive instructions for exchanging them [4]. Group 2: Company Overview - Acurx Pharmaceuticals is focused on developing a new class of antibiotics targeting difficult-to-treat bacterial infections, specifically Gram-positive bacteria [5]. - The lead product candidate, ibezapolstat, is ready for Phase 3 trials, with plans for international clinical trials next year, pending financing [5]. - The preclinical pipeline includes an oral product candidate for treating Acute Bacterial Skin and Skin Structure Infections and a development program for inhaled anthrax [5].

Core Viewpoint - Acurx Pharmaceuticals is preparing to discuss its Q2 2025 financial results and is advancing its lead antibiotic candidate, ibezapolstat, towards international Phase 3 clinical trials for treating C. difficile Infection (CDI) [1][4]. Company Overview - Acurx Pharmaceuticals is a late-stage biopharmaceutical company focused on developing a new class of small molecule antibiotics targeting difficult-to-treat bacterial infections [5]. - The company's lead product candidate, ibezapolstat, is designed to treat CDI and is ready for Phase 3 trials, with plans to initiate international clinical trials next year, pending financing [5]. Product Details - Ibezapolstat is a novel, orally administered antibiotic that acts as a Gram-Positive Selective Spectrum (GPSS®™) antibacterial, specifically targeting DNA polymerase IIIC to inhibit DNA replication in Gram-positive bacteria [3][5]. - The antibiotic has received positive regulatory guidance from the EMA, supporting its advancement to Phase 3 trials and potential submission for Marketing Authorization Application (MAA) in Europe [4]. Regulatory Status - Ibezapolstat has been designated as a Qualified Infectious Disease Product (QIDP) by the FDA, which provides incentives for the development of new antibiotics [4]. - The FDA also granted "Fast Track" designation to ibezapolstat for CDI treatment, highlighting the urgent need for new antibiotics in this area [4]. Upcoming Events - Acurx Pharmaceuticals will host a conference call on August 12, 2025, at 8:00 am ET to discuss its financial results and provide a business update [2].

Company Performance - Acurx Pharmaceuticals, Inc. (ACXP) has returned 0.8% year-to-date, outperforming the Medical sector, which has returned an average of -4.7% [4] - The Zacks Consensus Estimate for ACXP's full-year earnings has increased by 60.5% over the past quarter, indicating improved analyst sentiment and a stronger earnings outlook [4] Industry Ranking - Acurx Pharmaceuticals belongs to the Medical - Biomedical and Genetics industry, which has 502 stocks and is currently ranked 88 in the Zacks Industry Rank. This industry has lost an average of 4.8% year-to-date, showing that ACXP is performing better than its peers [6] - The Medical group, which includes Acurx Pharmaceuticals, is ranked 6 within the Zacks Sector Rank, indicating a relatively strong position among 16 sector groups [2] Comparison with Peers - BioCryst Pharmaceuticals (BCRX) has also outperformed the Medical sector with a year-to-date return of 32.6% and has a Zacks Rank of 2 (Buy) [5] - The consensus EPS estimate for BioCryst Pharmaceuticals has increased by 339.6% over the past three months, highlighting significant positive analyst sentiment [5]

Core Viewpoint - Acurx Pharmaceuticals has entered into a warrant inducement agreement to facilitate the exercise of existing warrants at a significantly reduced price, generating approximately $2.67 million in gross proceeds for the company [1][2]. Group 1: Warrant Inducement Agreement - The company has a warrant inducement agreement with a holder of existing warrants to purchase up to 4,445,435 shares at exercise prices between $3.25 and $3.26 per share, allowing the holder to exercise these warrants at a reduced price of $0.675 per share [1]. - In exchange for exercising the existing warrants, investors will receive 6,223,609 G-1 warrants and 2,667,261 G-2 warrants, totaling 8,890,870 new warrants [1]. - The G-1 and G-2 warrants are both exercisable at $0.425 per share and will expire five years from the issuance date [1]. Group 2: Use of Proceeds - The net proceeds from the warrant exercise are intended for working capital and general corporate purposes [2]. Group 3: Regulatory and Clinical Development - Ibezapolstat, the company's lead antibiotic candidate, is advancing to international Phase 3 clinical trials for treating C. difficile Infection (CDI) and has received FDA designations that may expedite its development [5]. - The antibiotic is part of a new class of drugs targeting Gram-positive bacteria, which includes significant pathogens like MRSA and VRE [6].